Background
Pleomorphic xanthoastrocytomas with anaplastic features (PXA-As) are rare tumors about which little is known regarding clinicopathological and molecular features. Several studies have identified BRAF V600E mutations in PXA-As, but the percentage with mutation may differ between adult and pediatric examples, and limited information exists about immunohistochemistry for IDH1 (isocitrate dehydrogenase 1). Design: 10 cases of adult PXA-As seen at our institution since 2000 were assessed for BRAF V600E mutation by polymerase chain reaction testing (PCR) and IDH1 by immunohistochemistry.
Results
Patients ranged in age from 18-68 years; 4 PXA-As affected temporal lobe and 2 were cystic. Four patients underwent gross total resection; and 9/10 received cranial irradiation and/or adjuvant chemotherapy. Five survived less than 5 years, although 2/5 died from non-tumor causes. Four long-term survivors are alive at 7.5, 9.8, 11.4, and 11.9 years post-diagnosis. 2 of 4 long term survivors had BRAF V600E mutation: patients were ages 18 and 28 years. A 48-year old male without BRAF mutation survives at 9.8 years, even with thalamic location; conversely a 68-year-old female with temporal lobe tumor and BRAF mutation survived 1.9 years after diagnosis. All tumors were IDH1 immunonegative.
Conclusion
This case series details clinicopathological features of a subset of rare PXA-As in adults. BRAF V600E mutation was identified in 50% of these cases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.